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A COMPARISON OF PATIENTS WITH FAMILIAL AND SPORADIC CUTANEOUS 
MELANOMA. 
Nina Jennifer Myerson Fisher (Sponsored by Jean Bolognia). Department of Dermatology, 
Yale University, School of Medicine, New Haven, CT. 
A comparison of patients with familial (n = 51) and sporadic (n = 163) cutaneous 
melanoma who attended the Yale Pigmented Lesion Clinic between January 31, 1995 and 
January 31, 1996 was performed. The two groups did not differ in their phenotypic 
characteristics or in the histologic subtypes, Breslow depth, or location of their 
melanomas. Familial melanoma patients were found to have a greater number of clinically 
atypical nevi (p = 0.02), to develop melanoma at a younger age (p = 0.05), to have had 
more skin biopsies of benign lesions performed prior to their diagnosis of melanoma (p = 
0.02), and to have had at least 3 histologically confirmed atypical nevi removed in the first 
five years after their diagnosis (p = 0.007). As a reflection of medical surveillance, the 
number of skin biopsies performed in both groups of patients and their histologic 
diagnoses were reviewed. Age had a positive correlation [0.20] with the total number of 
biopsies prior to the diagnosis of melanoma (p = 0.004). Independent of family history, 
the number of skin biopsies performed in the five years after diagnosis of the initial 
melanoma correlated positively with the physician’s estimate of the number of clinically 
atypical nevi (p = 0.0001). However, having had skin biopsies performed in the five years, 
two years or one year prior to the diagnosis of melanoma did not predict a thinner 
Breslow depth. Our data demonstrate that dermatologists routinely detect thinner 
melanomas than non-dermatologists, i.e., while < 0.40 mm (p = 0.05). Familial patients 

had more clinically atypical nevi and developed melanoma at a younger age. Therefore, 
one explanation for why medical surveillance did not predispose to thinner Breslow depths 
is the lack of total body skin examinations. 
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Introduction 
Melanoma represents a malignant proliferation of melanocytes and its incidence 
has been increasing worldwide (Cook, 1985). During the period 1980 to 1990, the 
number of melanomas diagnosed annually in the United States doubled while the 
population increased by only 11%. (Grin-Jorgensen, 1992) More specifically, the 
incidence has been increasing by approximately 5% per year. (Armstrong, 1992) The 
increasing incidence has been accompanied by a smaller increase in mortality. For 
example, while the incidence of melanoma increased approximately six-fold since 1950, 
the mortality rate from melanoma doubled. (Grin-Jorgensen, 1992) This increase in 
mortality argues in favor of a true increase in the incidence of the disease and not just of 
an increase in diagnosis. 
Because mortality rates have been shown to be directly proportional to the depth 
of invasion of the tumor, researchers have attempted to define risk factors that would 
allow identification of individuals who would benefit from medical screening and 
education concerning skin self-awareness. Risk factors predisposing to cutaneous 
melanoma include a personal history of melanoma, greater than 50 melanocytic nevi, 
greater than 5 atypical nevi, and lastly, a family history of melanoma. 
Few investigators (Barnhill, 1992; Grange, 1995; Kopf, 1986) have directly 
compared familial and sporadic cutaneous melanoma patients. Moreover, the proportion 
of familial melanoma patients in these studies was less than the proposed national 
incidence of 10%. This thesis will compare familial and sporadic cutaneous melanoma in 
a patient population with a higher proportion of familial melanoma. In addition, it will 
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analyze whether familial melanoma patients are aware of their increased risk of developing 
melanoma, and whether they therefore seek medical screening (e g., full body skin 
examinations). 
Familial Melanoma - Historical Perspective 
Although the article by Cawley (1951) is cited as the first to describe familial 
melanoma (Moschella, 1961), Norris (1820) actually described this entity 150 years 
earlier. In his article entitled “Case of Fungoid Disease”, Norris reports a male patient 
who developed a tumor on his lower abdomen at the site where a mole had been 
previously. The tumor was “nearly of half the size of a hen’s egg, of a deep brown colour, 
of a firm and fleshy feel, ulcerated on the surface”. The patient developed satellitosis and 
regional lymphnode metastases and died soon thereafter. At autopsy, there was evidence 
of metastases to multiple organs including the lung, liver and brain. Norris stressed the 
fact that the patient’s father had died of a similar disease approximately thirty years earlier, 
and that not only the father, but also the patient’s brother and children, had many moles. 
He concluded that the case “would incline [him] to believe that the disease is hereditary”. 
The next mention of familial melanoma in the literature is actually one of familial 
ocular melanoma. While ocular melanoma is not the focus of this review, this early 
recognition of a familial aspect deserves mentioning. Davenport (1926) described three 
generations, spanning from 1871 to 1926, in which two siblings of each generation had an 
ocular melanoma. He noted that the average age of the family members at the time of 
diagnosis was only 28.6 years. 
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In 1951, Cawley published a study of three individuals in one family who had 
melanoma. He discussed a 60-year-old man and his son and daughter, each of whom had 
multiple nevi, a fair complexion, light hair and blue eyes. The father and son developed 
metastases, and the son died as a result of his disease. Given the knowledge of hereditary 
melanoma in other animals and hereditary ocular melanoma, Cawley surmised that these 
cases of cutaneous melanoma had a hereditary component. He reasoned that if one of 
every eight to ten people living past the age of forty years died of cancer, the chance of 
three of five family members having cutaneous melanoma was 4.4 in a billion. 
After Cawley’s article, several reports of hereditary melanoma appeared in the 
literature (Table 1). Part of the apparent increase may have resulted from a new 
awareness of the entity familial melanoma, but a portion also may have resulted because of 
the increasing incidence of melanoma which was already occurring at that time. After 
these case reports, the number of affected patients became great enough to initiate studies 
consisting of only these patients. 
Further insight into familial melanoma came in 1978, when Lynch et al. published 
their article entitled “Familial Atypical Multiple Mole-Melanoma (FAMMM) Syndrome”. 
Lynch et al. (1978) based their autosomal dominant syndrome on a family in which three 
successive generations had either cutaneous melanoma or an atypical mole phenotype. 
These authors defined the atypical mole phenotype as multiple large moles with irregular 
borders and colors ranging from reddish brown to pink with signs of pigmentary leakage. 
They credit Clark (1976) as first suggesting that this phenotype might be associated with 
cutaneous melanoma. In support of Clark’s theory, the article also mentions a young 
i — m\m 
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female in whom a clinically suspicious mole, originally biopsied and diagnosed as an 
intradermal nevus with junctional activity, underwent malignant transformation within two 
years to a melanoma. 
The familial melanoma/precursor nevi syndrome acquired a second name in 1978, 
the B-K mole syndrome. (Clark, 1978) B-K moles were named after two patients with 
melanoma who originally presented with multiple nevi with distinctive clinical and 
histologic findings. The clinical definition of a B-K mole is included. The patients could 
have from less than 10 to greater than 100 nevi with predominance on the trunk, as well as 
nevi with diameter of approximately 10 mm, an irregular outline and a mixture of colors — 
tan, brown, black and pink. Clark et al. (1978) point out that the distribution of B-K 
moles was similar among family members. In addition, patients with the syndrome often 
had more nevi on non—sun-exposed surfaces than the general population. The authors felt 
that once patients were clinically identified, histologic confirmation was necessary to 
assign the patients this syndrome (Table 2). In addition to a compound nevus, one would 
see atypical melanocytic hyperplasia, mesenchymal changes within the papillary dermis and 
a lymphocytic infiltrate. 
Further support for an association between B-K moles and melanoma came from 
two patients with the syndrome and a prior diagnosis of melanoma who had a second 
primary melanoma diagnosed after changes were noted in a B-K mole through serial 
photography. (Clark, 1978) The authors reviewed prior reports of familial melanoma in 
the literature, such as Cawley’s family, and proposed that, in fact, these families would 
most likely qualify as the B-K syndrome. (Clark, 1978) 
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Familial Melanoma - Genetic Aspects 
As the first case reports of familial melanoma in humans were being published, 
investigators were already examining the genetic aspects of melanoma in other species. In 
1926, Caylor et al. reported that successive generations of swine developed metastatic 
melanoma. In addition, it was noticed in the 18th century that gray horses developed 
melanoma, and in the early 20th century. Van Dorssen (cited by Cawley, 1951) suggested 
that if gray horses lived long enough, all of them would eventually develop melanoma. 
Work in Drosophila also revealed the approximate location of a gene which might be 
responsible for generating melanoma. (Salamon, 1963) As early as 1915, it was known 
that if a gene in the Drosophila was homozygous, a melanotic tumor would develop, 
killing the larvae. Studies on salamanders revealed that melanoma has a faster growth rate 
in offspring than in the parents. (Cawley, 1951) 
After reviewing pedigrees of familial melanoma, most investigators believed that 
the genotype was inherited in an autosomal dominant pattern with incomplete penetrance. 
(Greene, 1983; Lynch, 1983) Using a pedigree analysis of four kindreds, Lynch et al. 
(1983) found evidence to support an autosomal dominant inheritance pattern among 
melanoma patients with a penetrance rate of 93%. However, when all of the family 
members with dysplastic nevi were included in the analysis, neither an autosomal dominant 
inheritance nor a purely environmental cause accounted for the distribution. The authors 
argued that because dysplastic nevi occur sporadically in a significant proportion of the 
population, the analysis would be invalid until sporadic and familial dysplastic nevi could 
be distinguished. (Lynch, 1983) 
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Anderson (1967) argued that certain cases of familial melanoma could result from 
recessive inheritance, as in the report by Moschella (1961) of two sisters. However, he 
believed that the pattern actually resulted from a lack of knowledge concerning the full 
family pedigree. (Anderson, 1967) Other clinicians believed that melanoma was a 
polygenic trait. (Anderson, 1967; Duggleby, 1981; Wallace, 1971) One group argued that 
polygenic inheritance was likely because the risk of melanoma in family members grew as 
the number of affected relatives increased. (Wallace, 1971) However, the authors note 
that polygenic inheritance cannot be differentiated completely from dominant inheritance 
with incomplete penetrance. (Wallace, 1971) 
Schoch (1963) began the search for a genetic explanation of human melanoma in 
1963. His family consisted of a mother and two sons with melanoma. Karyotypes of 
chromosomes from their peripheral blood leukocytes and dermal fibroblasts were normal. 
He concluded that a hereditary factor must exist to explain melanoma occurring in three 
family members, but the factor must exist at a sub-chromosomal level, e.g., at the level of 
genes. 
With new technology allowing DNA analysis, the search for both an abnormal 
allele in sporadic melanoma and a common allele in familial melanoma patients began. 
Genetic linkage analysis has proved to be a powerful method for mapping the location of 
genes, especially when they have classic Mendelian patterns of dominant, recessive or X- 
linked inheritance. (Piepkorn, 1994) Linkage analysis tests the hypothesis that a DNA 
polymorphism is co-inherited with a susceptibility to the disease in question, in this case 
melanoma. 
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Chromosomes 1 and 6 
The first results of linkage studies showed promising results for chromosomes 1 
and 6. In 1982, Pellegris et al. studied six families with familial melanoma and found that 
HLA-B12 was present in 5 of 6 families. They hypothesized that two complementary 
factors (one being the HLA complex on chromosome 6p) predisposed to melanoma and 
that the predisposition occurred in a dominant pattern with incomplete penetrance. 
(Pellegris, 1982) Greene et al. (1983) performed linkage analysis on 14 kindreds and 
found that a gene predisposing to dysplastic nevi and melanoma could be located on 
chromosome Ip near the Rh locus. Studies using two markers on chromosome 9 and 11 
showed no linkage. (Greene, 1983) 
The theory that the familial melanoma (MLM) locus resided on chromosome 1 
was discredited in 1987 by Gerhard et al., who found no association in either sporadic or 
familial patients with the Ha-ras-l allele. Four other groups also discredited chromosome 
1 as the site for the MLM locus, (van Haeringen, 1989; Cannon-Albright, 1990; Kefford, 
1991; Nancarrow, 1992a) The original studies that supported chromosome 1 as the MLM 
locus included patients with histologically confirmed atypical nevi but without a history of 
melanoma. The studies that discredited chromosome 1 included only those patients with 
melanoma. (Gerhard, 1987) 
Further proof that the MLM locus did not reside on chromosome 1 was provided 
by Nancarrow et al. (1992b). Using 172 microsatellite markers, they scanned all 
autosomes in 3 familial kindreds. They were able to exclude most of chromosome Ip. 
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Unable to exclude regions of 6, 9cen and 1 Oqter, they suggested further study of these 
regions. (Nancarrow, 1992b) 
In 1994, chromosome 6 was studied by Walker et al. Using linkage analysis, they 
found that a region between D6S105 and HLAF segregated with melanoma in 5 of 16 
familial kindreds. They found this surprising as these same families had shown previously 
linkage to chromosome 9, but the authors concluded that the families might be susceptible 
to melanoma because of a gene within the HLA region on chromosome 6. (Walker, 1994) 
Chromosome 9 
The idea of a tumor suppressor gene being responsible for melanoma formation 
was first suggested by studies of mouse melanoma cells and diploid fibroblasts. Jonasson 
et al. (1977) showed that a regular elimination of murine chromosome 4, which is 
homologous to human chromosome 9p, occurred. This supported the theory of a tumor 
suppressor gene.1 
Further localization of MLM came in 1992, when a woman without a family 
history of melanoma presented with eight primary cutaneous melanomas. Cytogenetic 
studies of her lymphocytes revealed a reciprocal translocation involving chromosomes 5p 
and 9p with the breakpoint near 9p21. (Petty, 1993a) In situ hybridization and gene 
dosage studies demonstrated a deletion of at least 6 Mb of chromosome 9p21. (Petty, 
1993b) This finding was consistent with the notion that her melanoma susceptibility arose 
via the loss of a tumor suppressor gene. 
Cannon-Albright et al. (1992) focused on the 9p21 region as it had been 
implicated by the presence of homozygous deletions in melanoma tumors (Fountain, 1992) 
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and the presence of a germline deletion in the above-mentioned woman. Using the 
D9S126 and interferon-a (IFNA) gene markers to perform linkage analysis on eleven 
large familial melanoma kindreds, they localized the MLM locus to the chromosomal 
region 9pl3-p22. (Cannon-Albright, 1992) Within two years. Cannon-Albright had 
confirmed her findings in more familial kindreds and had provided further localization. 
Using newly found markers, she found that the MLM locus resided in a 2-cM region 
proximal to D9S736 and distal to D9S171 (Table 3). (Cannon-Albright, 1994) 
Holland et al. (1994) did further deletion mapping on chromosome 9p using 
sporadic and familial metastatic melanoma specimens. Using markers spanning 19cM 
across 9p21-22, they found that 57% of the samples displayed an area of deletion. Two 
areas of common loss resided on either side of the IFNA marker. This was the first time a 
region distal to IFNA had been described, and the authors suggested that a second tumor 
suppressor might be involved. 
Further work supporting the theory that a MLM locus resided on chromosome 9p 
was done by Goldstein et al. (1994), who performed linkage analysis using markers IFNA 
and D9S126 on families previously examined in the chromosome lp linkage studies. They 
found evidence for linkage of the IFNA locus in 50% of patients with invasive melanoma, 
melanoma in situ and dysplastic nevi. Three pedigrees previously shown to have no 
linkage to lp now showed linkage to 9p, while 3 pedigrees which had shown linkage to lp 
were also linked to 9p; 2 pedigrees displayed linkage to neither chromosome. This 
reconfirmed the concept of heterogeneity among melanoma patients. The authors 
recognize that Cannon-Albright et al.’s (1992) research did not offer evidence of 
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heterogeneity but stress that both Cannon-Albright et al. (1992) and Nancarrow et al. 
(1992b) restricted their studies to melanoma, excluding dysplastic nevi. (Goldstein, 1994) 
Further studies by Goldstein (1996) simultaneously examined the two loci, lp and 9p, in 
these same families. For melanoma, the linkage to 9p was twice as strong. When 
dysplastic nevi were studied as well as melanoma, there was a comparable linkage with 
both lp and 9p. 
Isshiki et al. (1994) directly analyzed twenty microsatellite loci on chromosome 9 
from 25 uncultured, freshly excised melanoma tumors (22 sporadic and 3 familial). They 
found a loss of heterozygosity (LOH) affecting 9p in 72% of the melanomas. They found 
the same LOH in metastatic lesions in one patient and in a vertical growth phase tumor in 
another patient, supporting the theory that the mutation occurred early in tumorigenesis. 
In eleven cases, chromosome 9 was completely deleted, while in six cases, all or part of 
chromosome 9p was lost. The finding of a somatic interstitial deletion of 9p between 
D9S162 and D9S169 in one patient corresponded with prior localization of the MLM 
locus. (Isshiki, 1994) Similarly, Puig et al. (1995) utilized 12 microsatellite markers to 
analyze 54 paired melanoma and normal tissues. They reported a 54% LOH at 9p with 
one tumor having a homozygous deletion. 
MTS 1: The MLM Locus 
Genes that directly regulate the cell cycle are likely candidates for tumorigenesis. 
Kamb et al. (1994) recognized that within the 2-cM region on chromosome 9 proximal to 
D9S736 and distal to D9S171 lay the Multiple Tumor Suppressor 1 (MTSl)2gene that 
encodes plG0^4, the inhibitor of cyclin-dependent kinase 4 (CDK4). In the cell cycle, 
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pi6^4 forms a complex with the D-type cyclins to prevent passage through the Gi phase 
of the cell cycle. Normally, the binding of cyclins to cyclin-dependent protein kinases 
(CDK) allows the phosphorylation of CDK, and therefore activation. The active unit is 
then inhibited by phosphorylation of another amino acid pair or by binding to CDK 
inhibitory subunits (CKI). pl6INK4, along with pl5INK4B, is structurally related to CKIs 
specific for CDK4- and CDK6-cyclin complexes. pl6INk4 is a protein, consisting of four 
tandemly repeated ankyrin domains, which binds to and inhibits the catalytic activity of the 
CDK-cyclin complex, thereby preventing the phosphorylation of the retinoblastoma gene 
product. (Morgan, 1995; Parry, 1996) Therefore, the inactivation of the pl6INK4 inhibitor 
would promote tumorigenesis. UVC irradiation has been shown to cause a large increase 
in the pl6INK4 protein, delaying cells in the Gi phase of the cell cycle, which resides as the 
levels of pl6INK4 decrease. (Wang, 1996) 
In this original study, Kamb et al. (1994) found that MTS1 was deleted 
homozygously in many tumor cell lines, including astrocytomas, glioma, breast, 
osteosarcoma and kidney. Furthermore, in the melanoma cell lines that carried at least one 
copy of the gene, there were often nonsense, missense or ffameshift mutations in the gene. 
They found eighteen mutations in 14 of 34 melanoma cell lines. Additional studies of 
human non-small cell lung carcinomas showed that MTS1/CDK4I mutations, either 
deletions or missense, were present in 19 of 64 tumors, suggesting that inactivation of this 
gene was important during carcinogenesis. (Hayashi, 1994) Okamoto et al. (1994) found 
that neither p^11^4 nor the RB protein was present in 28 of 29 tumor cell lines from 
human lung, esophagus, liver, colon and pancreas. In addition, they found that 
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homozygous deletions of MTS 1 were present in many of the cell lines and that 
transfection of the MTS1 cDNA expression vector into carcinoma cells inhibited the 
colony forming efficiency. These transfected cells also were selected against with 
continued passage in vitro. 
Nobori et al. (1994) also reported the presence of MTS 1 mutations within 
multiple tumor cell lines. Using positional cloning on 46 human malignant cell lines, they 
found that the most frequently deleted region resided within 9p21. Polymerase chain 
reaction (PCR) analysis revealed homozygous deletions of the MTS1 fragment in 61% of 
melanomas, 87% of gliomas, 36% of non-small-cell lung cancers and 64% of leukemia cell 
lines. While the MTS1 gene transcripts were not present in tumor cell lines, reverse 
transcriptase PCR showed that they were present in normal cells. Notably, the authors 
also reported a germ-line nonsense mutation within this gene in a patient with the 
dysplastic nevus syndrome. This provided further support that MTS1 was the MLM 
locus. 
To prove that mutations in MTS1 occurred in vivo and not just as artifacts of in 
vitro cell culture formation, analysis of actual tumors had to be performed. Ohta et al. 
(1994) tested for somatic mutations in this gene using DNA from 30 surgically resected 
metastatic melanoma tumors, both cutaneous and uveal in origin, from sporadic melanoma 
patients. No mutations were found in the coding region of MTS 1 in the uncultured 
tumors, but mutations or deletions were detected in 60% of the cultured melanoma cell 
lines DNAs. This agreed with prior sequencing of uncultured tumors of various other 
organs. From their results, the authors concluded that the MTS1 was a likely candidate 

13 
for the MLM gene, but that another gene on 9p21 might be the target of the frequent 
LOH in melanomas. In addition, if the MTS1 were the MLM gene, it might be inactivated 
by homozygous deletion or by another mechanism which would not alter the coding 
sequence of the gene. Later studies by Ohta et al. (1996) re-examined whether the allelic 
loss of 9p21 observed in sporadic cutaneous melanoma included the MTS1 locus. Using 
similar methods to above but with new microsatellite markers, they found that somatic 
mutations of the locus are rare (3.1%) in sporadic melanomas with allelic loss being more 
common (63%). This again suggested that genes other than MTS1 in the 9p21-23 region 
might be involved in the development of melanoma. 
Similarly, Gruis et al. (1995c) studied primary bladder carcinomas along with 
primary and metastatic melanomas and reported mutations of MTS 1 in 3 of 33 bladder 
carcinomas and 5 of 34 melanomas. Although other authors found that homozygous 
deletions were two to three times more common than mutations (Kamb, 1994a), Gruis et 
al. (1995c) did not look for chromosomal deletions within these samples, because the 
presence of some normal cells within their tissue would bias the results. 
As Kamb et al. (1994a) had already identified homozygous deletions in 75% of 
melanoma cell lines, suggesting that the MTS1 locus acted as a tumor suppressor gene, 
Hussussian et al. (1994) studied whether the mutations or deletions of MTS 1 
cosegregated with the 9p21 linked familial melanoma patients. They found that within 
their 18 families, while a majority of the melanomas occurred in patients with dysplastic 
nevi, only 30% of dysplastic nevi cases had detectable MTS1 mutations while 92% of the 
melanoma cases had a mutation. This suggested that while the MTS1 mutations may be a 
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cause of melanoma, they were not a cause of dysplastic nevi. They also found that in their 
familial patients who linked to 9p21, 4 of 6 families had MTS1 mutations. Hussussian et 
al. (1994) proposed that in the two families without mutations, there might be a silent 
mutation or a normal MTS1 gene which is tightly linked to a different hypervariable locus 
whose mutations led to melanoma development. They concluded that while their data was 
consistent with the identification of MTS 1 as the MLM gene, mutations or deletions 
within the gene were not necessary for melanoma development within familial patients. 
Kamb et al. (1994b) then did further studies to determine whether their prior 
observation of point mutations in MTS1 in melanoma cell lines segregated with melanoma 
susceptibility in 9p-linked pedigrees. Although they found two potential mutations of the 
gene in cell lines, they found no disruptive MTS1 mutations in the pedigree patients. The 
authors suggest that the low incidence of observed mutations might signal that MTS1 and 
the MLM gene are separate and distinct genes or that the majority of predisposing 
mutations occur outside the pi 6 coding region. Given all of the previous data suggesting 
that this gene was in fact the MLM gene, the authors suggest that because mutations in 
MTS 1 had been reported in malignant tumors, other than melanoma, a mutation in this 
gene might just predispose to any cancer within linked families. 
Further support for those who believed in the heterogeneity of malignant 
melanoma was provided by MacGeoch et al. (1994), who studied six melanoma families in 
England using linkage analysis. They reported that only 3 of 6 families were linked to 
9p 12-23. A study of Australian pedigrees by Holland et al. (1995) also suggested the 
heterogeneity of MLM. Mutation analysis of MTS 1 in 17 pedigrees revealed only one 
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family with a germline mutation in exon 1 along with two previously reported 
polymorphisms of an untranslated region in exon 3. Walker et al. (1995) performed a 
similar study in 18 melanoma families and discovered that 7 of 18 pedigrees segregated 
with MTS1 mutations. Within the 7 pedigrees, 46 of 51 family members with melanoma 
segregated with the mutations. The remaining cases were assumed to be sporadic.3 
Another study analyzed 14 melanoma cell lines with varying metastatic potential in nude 
mice, and discovered mutations of MTS 1 in 3 of 14 lines and homozygous deletions in 6 
of 14 lines. (Luca, 1995) Gruis et al. (1995b) analyzed 15 Dutch familial pedigrees and 
found that 13 of 15 contained a 19 basepair germline deletion causing a reading frame 
shift.4 Borg et al. (1996) reported that 2 of 10 Swedish kindreds had a novel germline 
mutation in exon 2. Analysis of 33 consecutive familial melanoma patients revealed 
mutations in 5 of 28 unrelated patients. Fitzgerald et al. (1996) speculate that the number 
of mutations is lower than in the studies using large kindreds because other effects, such as 
excessive sunlight exposure, would be more likely to affect two to three family members in 
this study compared with the larger numbers in the kindred studies. 
Further proof that MTS1 was the MLM gene was provided by a kindred with 
multiple family members who had melanoma and/or pancreatic cancer. (Whelan, 1995) 
All of the affected family members shared a mutated allele (Gly93Trp) of MTS 1 along 
with a wild-type allele, while the unaffected members were homozygous for the wild-type 
gene. 
Maestro et al. (1995) took a different view in arguing that mutations within 
MTS1 predisposed to melanoma. Knowing that p53 mutations occurred in sun-related 
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tumors such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), they 
analyzed melanoma cell lines. Their results displayed an excess of C:G to T:A transitions 
at adjacent pyrimidine sites which is identical to those induced by UV radiation in BCC 
and SCC. They interpreted the information as strong support for UV radiation causing 
melanoma. Kamb (1995) responded to this new data and suggested that while Maestro et 
al. (1995) were correct in their interpretation, the data also supported the idea that the 
point mutations they had found occurred in vivo and were not an artifact of cell culture. 
Pollock et al. (1995) performed a similar experiment on 30 melanoma cell lines. They 
discovered that 19 of 30 lines carried partial or complete homozygous deletions. In 
addition, of the remaining cell lines, 8 were shown by direct sequencing by PCR to have a 
total of 9 different mutations within exon 1 and exon 2. The highest mutation rate was 
found to be C:G to T:A transitions, which agrees with Maestro et al.’s (1995) results. 
Similarly, the authors concluded that UV radiation plays a role in melanoma formation and 
that the target is MTS 1.5,6 (Pollock, 1995) 
Because of its similarity in structure to MTS1 and its close location on 
chromosome 9p (<35kb), the pi5 gene was studied as a possible MLM. The pi5 gene, 
also known as MTS2, is induced by TGF-|3 and is thought to cause Gi arrest either by 
growth inhibition or cell contact inhibition. It is known that approximately 80% of 
homozygous deletions that inactivate MTS1 also inactivate the pi5 gene. The authors 
searched for pi5 gene mutations in tumor cell lines and for linkage with melanoma 
kindreds, but were unable to find any mutations. They concluded that although pi5 plays 
a role in growth regulation, it was an unlikely candidate for the MLM. (Stone, 1995) 
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Glendening et al. (1995) found homozygous deletion of the pi 5 gene in six 
metastatic melanoma cell lines in addition to hemizygous loss of MTS 1. The p 16 protein 
was present within all of the lines. They concluded that the loss of one allele was enough 
to signal melanoma formation. As Gruis (1995b) had reported a living patient with a 
homozygous deletion, Glendening et al. (1995) argued that this is biologically equivalent 
to a 50% loss in function and that a redundancy in the genome, possibly provided by the 
pi5 protein, compensated for the loss. 
Further answers to the mechanism of MLM came from a study of cell lines from 
head and neck squamous cell carcinomas and from a variety of non-melanoma primary 
tumors. Having already discovered a de novo methylation of a 5’ CpG island that caused 
a transcriptional block of full-length pl61NK4, Mao et al. (1995) identified alternative 
MTS1 transcripts of a sequence in exon IB in both unmethylated and methylated cell lines. 
The authors suggest that this different sequence might alter cell cycle regulation. 
To strengthen the argument that MTS 1 corresponded to the MLM gene, the 
biological importance of the protein needed to be proven. Liu et al. (1995) proved that a 
mutated form of the gene encoded a dysfunctional protein. They described a family in 
which a mutation in exon 2 segregated with the disease. In fact, 3 of 3 family members 
with melanoma displayed the mutation in addition to two elderly family members without 
melanoma. As had been cited previously, the authors argued that obligate carriers do not 
necessarily display the disease and that because of the current increase in UV radiation 
exposure, the younger generations are more likely to develop melanoma. (Cannon- 
Albright, 1994; Battistutta, 1994) They reported that the protein did not bind CDK4 in 
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vitro, thereby losing its inhibitory function, and that in vivo, the mutated gene failed to 
inhibit formation of G418-resistant colonies in a transfection assay while the wild types 
succeeded. They concluded that MTS1 was indeed the MLM gene that predisposed to 
melanoma but that other genetic or epigenetic factors participated in tumorigenesis. (Liu, 
1995) 
Reymond et al. (1995) also studied the function of the mutant pl6INK4 protein. 
They found that most variants were deficient in interacting with CDK4 and CDK6. These 
results were consistent with the theory that a decrease in CDK interaction predisposes 
individuals to an increased risk of cancer. Wick et al. (1995) studied both pl6INK4-CDK4 
binding and CDK4/D1 kinase activity and found that the melanoma-associated mutants 
were defective. Koh et al. (1995) demonstrated that several tumor-derived alleles of 
MTS1 of osteosarcoma origin encoded dysfunctional proteins in vitro, causing a lack of 
inhibition in progression through the Gi phase of the cell cycle. In vivo, they proved that a 
functional retinoblastoma protein is necessary but not sufficient for full sensitivity to 
p 16INK4_mediated inhibition. Parry et al. (1996) described a variety of pl6INK4 mutations, 
some of which caused altered function while others did not. Some were found to be 
temperature-sensitive for pl6INK4 protein binding to CDK4 and CDK6 in vitro, for 
inhibiting cyclin activity, and for increasing the proportion of Gi-phase cells. 
The biological significance of a dysfunctional pl6INK4 complex was further 
elucidated when it was found that the mutated complex acted as a tumor-specific antigen 
recognized by autologous cytolytic T lymphocytes. (Wolfel, 1995) The mutated CDK4 
was present in autologous cultured primary melanoma and metastatic tissues but not 
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within the patient’s lymphocytes. The point mutation, an arginine-to-cysteine exchange, 
was present in 2 of the 28 melanomas analyzed. The mutation prevented binding of the 
pl£iNK4 protejn but not t0 0ther CDK4 inhibitors. This same mutation was reported in a 
kindred in which 11 of the 11 melanoma patients had it along with 2 of 17 unaffected. 
(Zuo, 1996) The mutation was found to alter the pl61NK4 protein binding site but did not 
affect the ability of CDK4 to bind to cyclin D and form a functional kinase. This mutation 
appeared to act as a dominant oncogene. 
Another tactic taken to prove that MTS 1 corresponded to the MLM was to 
demonstrate that mutations within the gene correlated with metastatic potential. Varying 
results have been reported. Studying human melanoma cell lines with varying metastatic 
potential in nude mice, Luca et al. (1995) found no correlation between the presence of a 
mutation within or deletion of MTS 1 and metastatic potential. In contrast, Puig et al. 
(1995) studied 54 paired melanoma tissues and normal tissues and found that 87.5% of the 
genes with large deletions were associated with a high risk of metastases compared with 
those without deletions or with a loss of fewer than 8 micro satellite markers. Using 
immunohistochemistry to evaluate the expression of the plb11^4 protein, it was found that 
while loss of expression was not necessary for melanoma formation (Reed, 1995; 
Glendening, 1995), its loss was more likely to be related to the tumor’s invasiveness or 
ability to metastasize. The protein was partially or completely absent in 53% of the 
primary tumors and 72% of the metastatic tumors. (Reed, 1995) 
In summary, linkage analysis, LOH studies and studies of a woman with a 
reciprocal translocation involving chromosomes 5p and 9p all support chromosome 9p as 
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containing the MLM locus. Further investigations have found that MTS1, a tumor 
suppressor gene involved in regulation of the cell cycle, is most likely the MLM locus. 
Materials and Methods 
Patients were eligible for the study if they had at least one invasive cutaneous 
melanoma. The diagnosis of an in-situ melanoma was not sufficient for entry into the 
study, but some of the patients with multiple primary melanomas had in-situ lesions. Of 
note, in the patients with multiple primaries, the invasive melanoma was not always their 
initial cutaneous melanoma. Melanoma stage in the multiple primary patients was based 
upon the most advanced lesion. Two hundred and eighteen patients meeting these criteria 
visited the Yale Pigmented Lesion Clinic between January 31, 1995 and January 31, 1996. 
Four patients were excluded from the statistical analysis because their family history of 
melanoma was unknown. 
Patient information was obtained through chart review, questionnaires, patient 
visits, and telephone interviews. Upon entering the clinic, patients completed an 
epidemiologic questionnaire that addressed family history of melanoma, nevi and skin 
cancer, the patient’s personal assessment of number of nevi and their characteristics, 
personal and family history of non-cutaneous malignancies, occupation, UV light 
exposure, and phenotypic characteristics. 
A full-body skin examination was completed by a physician at the time of each 
visit to the clinic. The total nevus count was ascertained from the patient’s first visit. The 
total number of clinically atypical nevi and actinic keratoses included those recorded from 
the patient’s first clinic visit through January 31, 1996. At the patient’s first clinic visit, 
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the nurse recorded all previous skin biopsies and their approximate dates as well as the 
name of the physicians who had performed any skin biopsies or surgical excisions. With 
patient consent, the pathology reports were obtained, as were the medical records from 
previous physicians. The latter allowed a further review of the number of biopsies. 
Multiple attempts were often necessary in order to obtain both the reports and records. 
Only histologically confirmed biopsies were included in the analysis. Previous and 
subsequent skin biopsies were recorded chronologically in relationship to the patient’s 
melanoma(s) and according to type. The four subgroups of biopsy specimens were: (1) 
atypical nevi based upon architectural disorder and cellular atypia (National, 1992), (2) 
benign nevi, (3) non-melanoma skin cancers (BCC, SCC, keratoacanthoma), and (4) 
benign (non-nevi) lesions. One analysis included only the number of skin biopsies 
performed in the five years prior to and in the five years after the diagnosis of melanoma. 
If five years had not yet passed since the diagnosis of melanoma, blanks were inserted in 
calculating the number of biopsies so as not to assume that the patient did not have 
biopsies in those given years. 
The histologic slides of all the melanomas diagnosed at outside institutions were 
re-read by one of the dermatopathologists in our department utilizing standard criteria. 
(Lever, 1990) In addition, slides that originally had been read at Yale but did not have 
complete descriptions were re-reviewed. Those melanomas that could not be clearly 
classified histologically were labeled ‘unclassified’. Medical documentation, via 
pathologic reports, of family members with melanoma was attempted for each patient with 
a positive family history. Relatives’ information obtained by death certificate or medical 
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records was considered clinically confirmed but not histologically confirmed. Family 
members’ melanomas were considered confirmed for the purpose of statistical analysis 
only if histologically documented by a pathology report. 
Data collection was done by the author with review by a physician. Statistical 
analysis was performed using SAS programming. Data were entered by a neutral party 
using KP-5, a data entry program written by Peter Charpentier at Yale University, and 
were then verified. Chi-square tests, t-tests, correlations and unconditional logistic 
regression were used to analyze the data. In instances where more than 20% of the cells 
in the chi-square test had expected values of less than five, the Fisher’s exact (two-tailed) 
test was used to assess significance (p < 0.05). Data was broken into subgroups based on 
accepted standards or on the nature of the data ascertained by univariate analysis. All 
tests that examined the potential effect of family history were run in triplicate, i.e., patients 
with no family history (“sporadic patients”) were compared to: (1) all familial patients 
[group 1], (2) patients with a positive history in a first-degree relative [group 2], and (3) 
patients with a confirmed melanoma history in a first-degree relative [group 3], 
Results 
Patient Characteristics 
All 218 melanoma patients who attended the Yale Pigmented Lesion Clinic from 
January 31, 1995 to January 31, 1996 were Caucasian. As seen in Table 4, there was no 
significant difference in the sex of the patients in the familial melanoma group (n = 51) 
versus the sporadic melanoma group (n = 163) (all patients: F 61.2%; M 38.8%). Two 

23 
patients were immunosuppressed, both due to infection with the Human 
Immunodeficiency Virus. 
Of the 214 patients included in statistical analysis, 51 (23.6%) had a positive 
history of familial melanoma (“familial patients”). Of this group, 6 patients had two 
affected relatives, one patient had three affected relatives, and one patient had eight 
affected relatives. Of the familial patients, 31 (60.8%) had at least one first-degree relative 
with the diagnosis of melanoma while 20 (39.2%) patients had only second-degree 
relative(s) affected. Pathology reports were obtained for 85.3% of the first-degree 
relatives (Table 5) and 70.6% of the second-degree relatives. Approximately the same 
proportion of females and males reported a family history (25.3% versus 21.7%, p = 
0.62). Two of the familial patients had relatives diagnosed with melanoma after their own 
diagnosis. These two patients were excluded from those statistical analyses that examined 
screening prior to the diagnosis of melanoma. 
As mentioned previously, all tests that examined the potential effect of family 
history were run in triplicate, i.e., patients with no family history (“sporadic patients”) 
were compared to: (1) all familial patients (n = 51, group 1), (2) patients with a positive 
history in a first-degree relative (n = 31, group 2), and (3) patients with a confirmed 
melanoma history in a first-degree relative (n = 26, group 3). Unless otherwise specified, 
the results are from the comparison of sporadic patients to group 1. The comparison of 
sporadic patients to groups 2 and 3 did not produce statistically significant results but 
contained a similar trend to the results found when using group 1. 
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The age of familial patients at the first diagnosis of melanoma was significantly 
different from that of sporadic patients (p = 0.05). Familial patients were more likely to be 
diagnosed with melanoma at a younger age. As seen in Table 4, 64.7% of the familial 
patients were diagnosed between the ages of 25 and 45 years while only 44.5% of the 
sporadic patients were. In addition, 48.5% of the sporadic patients were diagnosed over 
the age 45 years as compared to 31.3% of the familial patients. When age was examined 
as a continuous variable, however, the t-test results displayed no significant difference (F = 
41.8 + 12.3 yrs; S = 45.4 + 14.6 yrs, p = 0.09). 
As seen in Table 4, there was no significant difference in the hair color or eye 
color of the two groups. In addition, the patients’ estimates of their own skin’s 
susceptibility to sunburn and ability to tan were similar. As everyone in the study had the 
diagnosis of invasive melanoma, one would expect a majority of the patients to have 
lighter hair and eye color along with a susceptibility to burning and an inability to tan. 
(Armstrong, 1992) Questions concerning sun exposure both in terms of time outdoors 
and percentage of time wearing different strengths of sunscreen cannot be considered 
valid, because some patients answered for current post-melanoma practices while others 
answered based on prior practices. Females were much more likely to have visited a 
suntanning parlor at least once (F = 88.8%; M = 11.5%, p = 0.001). Patients who had 
visited a salon had a younger average age than those who reported no visits (Y = 38.2 + 
10.4 yrs; N = 46.0 + 14.5 yrs, p = 0.0004). No significant difference existed between 
sporadic and familial patients in their likelihood of having visited a suntanning salon (p = 
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0.82). A majority of subjects (60%) had visited a salon less than ten times. The greatest 
number of visits was 60. 
The remaining phenotypic characteristics studied were the patients’ and the 
physician’s estimate of the total number of nevi and atypical nevi. No significant 
difference existed between familial and sporadic patients concerning the physician’s 
estimate of total number of nevi (p = 0.61). Approximately 50% of the patients in each 
group fell into the subgroup of 0-32, while approximately 25% of patients in each group 
fell into the subgroups of 33-66 or > 66. The physician’s estimate of the number of 
atypical nevi was significantly higher among familial patients (p = 0.02). Equal 
proportions of patients had 2-5 clinically atypical nevi (F = 37.2%; S = 37.6%), but a 
greater proportion of sporadic patients had 0-1 clinically atypical nevi (F = 17.7%; S = 
32.7%) while a smaller proportion had either 6-10 or greater than 10 clinically atypical 
nevi (F = 45.1%; S = 29.7%, p = 0.02). Of interest, the estimated number of total body 
nevi did correlate positively with the number of recorded clinically atypical nevi (p = 
0.0001). 
Most patients in the study (86%) had at least one clinically atypical nevus, and 
approximately 70% of patients in both the familial and sporadic groups had histologically 
confirmed atypical nevi (p = 0.10). (National, 1992) The distribution of atypia of the nevi 
among the two groups was roughly the same (p = 0.20), with most nevi having mild 
atypia. It bears noting that while most of the nevi were diagnosed at this institution, there 
is a significant discrepancy among institutions in the classification of atypia as mild, 
moderate, or severe. 
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The majority of the patients in both the sporadic and the familial melanoma 
groups did not have a history of a non-melanoma skin cancer. No significant difference 
existed between the two groups (p = 0.24). In addition, no difference existed between the 
familial and sporadic groups in the type of non-cutaneous malignancies (p = 0.70). 
In multivariable analysis (Table 6), a family history of non-melanoma skin cancer 
(OR = 2.08; 95% Cl = 1.07 to 4.05), a surrogate report of atypical nevi in family members 
(OR = 2.27; 95% Cl = 1.16 to 4.43), and the presence of a secondary primary melanoma 
(OR = 2.40; 95% Cl = 1.12 to 5.15) predicted a positive family history of melanoma. 
Melanoma Characteristics 
The distribution of the sites of initial primary melanomas was similar to previously 
reported series. (Armstrong, 1992) As seen in Table 7, melanomas were more likely to 
occur in females on upper or lower extremities, while men had significantly more 
melanomas at all other sites (p = 0.001). This significant difference between females and 
males existed among both familial patients (p = 0.008) and sporadic patients (p = 0.001). 
When patients of both sexes were grouped together, there was no difference between 
familial and sporadic patients in the distribution of melanoma sites (p = 0.30). Notable 
characteristics of familial patients, compared to sporadic patients, were a larger proportion 
of males having melanomas of the anterior trunk while an equal proportion of the sexes 
had melanomas of the posterior trunk (p = 0.008). The anatomical distribution of 
melanomas among sporadic patients was similar to the expected distribution described 
above, with females having the greatest proportion of tumors on the legs and males having 
the greatest proportion on the posterior trunk (p = 0.001). (Armstrong, 1992) 
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With respect to histologic diagnoses and Breslow depths, no significant 
differences existed between familial and sporadic patients, as seen in Table 7. Nodular 
melanomas were deeper than superficial spreading or lentigo maligna melanomas at the 
time of diagnosis. The majority of nodular melanomas had Breslow depths >0.75 mm at 
the time of diagnosis. 
As expected from the similar Breslow depths, the distribution of melanoma stages 
and the outcomes were similar in familial and sporadic patients (p = 0.18; 1.0, 
respectively). By the nature of the study, all patients were alive upon entry, and only two 
patients died while three currently have evidence of metastatic disease. Only six patients 
ever had evidence of metastatic disease. This is not surprising as the patient population 
consisted of many patients who had a dermatologist, and not an oncologist, as their 
primary caregiver for their melanoma. 
No difference existed between the treatment of melanoma in the familial and 
sporadic patients. All patients had excisions, and both groups contained patients with 
lymphadenectomies. The margins of excision in the familial and sporadic groups were 
considered equal (F = 1.7 + 1.4 cm; S = 1.7+ 1.1 cm, p = 0.05). Few patients had 
received additional treatment such as vaccination, chemotherapy or radiation. 
Multiple Primaries 
Eighty-three percent of the patients (n = 177) had only one cutaneous melanoma. 
Twenty-five patients had two melanomas, 10 patients had three melanomas and 6 patients 
had four or more. In contrast to the initial cutaneous melanomas, where patients were 
most likely to have noticed a suspicious lesion, dermatologists discovered a majority 
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(80%) of the second primary tumors (F 87.5%; S 75%, p = 0.25). The majority of second 
primaries (72.5%) were diagnosed within five years of the diagnosis of the initial 
melanoma, with approximately half of the diagnoses made within the first year. No 
differences existed between the familial and sporadic groups with regard to multiple 
primaries or in the intervals during which they developed (p = 1.00; 0.83, respectively). 
On average, in the first five years after the initial melanoma diagnosis, one of every 142.9 
biopsies of atypical nevi [group A] and benign nevi [group B] was a second primary 
melanoma. When the denominator includes non-nevi benign [group C] lesions (i.e., 
A+B+C), a second primary melanoma was diagnosed for every 200 skin biopsies 
performed. 
The Breslow depths of subsequent melanomas were thinner than the originals. 
When looked at as a continuous variable, initial melanomas were found to have thicker 
Breslow depths than subsequent melanomas (p = 0.01). Only 32% of initial melanomas 
were less than or equal to 0.40 mm, while 56% of subsequent lesions fell into this group 
(p = 0.35). The Breslow depths of second primaries were similar for familial and sporadic 
patients. Among those patients who had discovered their initial melanoma, 10.5% again 
noticed their subsequent lesions, while 84.2% of such lesions were noted as suspicious by 
a dermatologist. Most (99%) of the second primary melanomas were diagnosed 
histologically either as superficial spreading melanomas or in situ lesions. 
Predictors of Breslow Depth 
As discussed above, a personal history of melanoma was predictive of a thinner 
Breslow depth (p = 0.01), while a family history of melanoma was not (p = 0.56). 
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Whether or not the patient had skin biopsies performed within the five years prior to the 
first melanoma diagnosis — including atypical nevi [A] (p = 0.39), benign nevi [B] (p = 
0.30), non-nevi benign lesions [C] (p = 0.20), non-melanoma skin cancer [group D] (p = 
0.15), or a combination of A+B+C+D (p = 0.53) — did not influence the Breslow depth. 
Likewise, having had a skin biopsy performed in the two years or one year preceding the 
diagnosis of melanoma did not predict a thinner Breslow depth (p = 0.50 and 0.40, 
respectively) (Table 9). Age was not predictive of Breslow depth among males, females 
or both when grouped (p = 0.15-0.52); however, a positive correlation between age and 
Breslow depth did exist (p = 0.03). Use of artificial UV light for tanning purposes did not 
predispose to thicker lesions (p = 0.18). The patients who frequented the salon greater 
than ten times were not more likely to have a thicker lesion at diagnosis (p = 0.11). 
For all patients, the anatomical site of the melanoma was predictive of Breslow 
depth. Melanomas of the head and neck or lower extremities were more likely to be > 1.5 
mm in depth (p = 0.04), although a majority (77.4%) were still <1.5 mm. In females, site 
did not correlate with depth (p = 0.69). Among males, however, lesions of the head and 
neck were equally likely to be > 1.5 mm as < 1.5 mm (p = 0.03), while lesions of the trunk 
or extremities were more likely to be < 1.5 mm (p = 0.03). 
An analysis of who noticed the first melanoma as a predictor of Breslow depth 
yielded interesting results. As seen in Table 9, when the patient noticed the suspicious 
lesion as opposed to a friend, family member or physician, the Breslow depth was more 
likely to be 0.41-4.00 mm as opposed to < 0.40 mm (p = 0.005). The same was true if a 
patient noticed the lesion as opposed to a physician (p = 0.001). Dermatologists 

30 
discovered more of the melanomas that were diagnosed while still <0.75 mm in depth 
than did other physicians (p = 0.03). In fact, a majority of lesions diagnosed by 
dermatologists were < 0.4 mm in depth (p = 0.05). Dermatologists, compared to non¬ 
dermatologists, did not discover more melanomas in those patients with more clinically 
atypical nevi or with histologically confirmed atypical nevi (p = 0.18; 0.09, respectively). 
Biopsies Pre- and Post- First Melanoma 
The average number of skin biopsies performed in the five years prior to the 
diagnosis of melanoma was 0.7, while the average total number at any time prior to the 
diagnosis was 1.1. Age had a positive correlation [0.20] with the total number of biopsies 
prior to melanoma (p = 0.004). When comparisons of all types of biopsy combinations 
were made (e.g., A,B,C,D or various combinations of the types), familial patients were 
more likely than sporadic patients to have had benign nevi biopsied at any time prior to 
their melanoma (p = 0.03); this was not true when looking at any of the biopsy 
combinations in the five years prior to the diagnosis of melanoma (Table 8). 
The average number of skin biopsies performed was 5.6 in the first five years after 
the melanoma was diagnosed and 8.1 from the time of diagnosis through January, 1996. 
The average length of follow-up was 77.5 months after the diagnosis of the first 
melanoma. Independent of family history, the number of skin biopsies performed in the 
first five years after the diagnosis of the first melanoma correlated positively with the 
number of clinically atypical nevi (p = 0.0001). Familial patients were more likely to have 
had more than two histologically confirmed atypical nevi removed in the first five years 
after the diagnosis of their initial melanoma, while sporadic patients were more likely to 
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have had 0 or 1-2 biopsies of atypical nevi (p = 0.007). Patients with a second primary 
melanoma were more likely to have had > 5 biopsies in the first five years after the first 
melanoma, while patients with only one primary tended to have 1-5 biopsies (p = 0.001). 
Patient Perceptions 
In general, patients were able to assess the condition of their own skin, as 
reflected in a comparison of the physician analysis with patient answers to the 
questionnaire. When compared to the physician estimate of total body nevi, patients 
correctly estimated their number of nevi (p = 0.001) and whether they had more nevi (p = 
0.001) or larger nevi (p = 0.02) than the general population. Familial patients with a 
history of histologically confirmed atypical nevi thought that they had more nevi than 
average (p = 0.02) and that they had irregular nevi (p = 0.005). Importantly, a majority of 
patients who had atypical nevi biopsied prior to their melanoma diagnosis were aware that 
they had more than an average number of nevi (p = 0.001) and irregular nevi (p = 0.02). 
In fact, patients with greater than 5 histologically proven atypical nevi removed prior to 
the diagnosis of their melanoma were more likely to think that their nevi were irregular 
than were patients with no prior histologically confirmed atypical nevi or 1-5 histologically 
confirmed atypical nevi (p = 0.02). When patient perceptions were compared to the 
physician estimates of the number of clinically atypical nevi, patients with greater than 5 
clinically atypical nevi felt that they had more nevi than the general population (p = 0.001) 
and that these nevi were irregular in shape (p = 0.04). Patients whose melanoma was 
discovered by a dermatologist, as opposed to a non-dermatologist, were more likely to 
think that they had more nevi than average (p = 0.04). 
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The patients who had noticed a suspicious lesion, which was in fact a melanoma, 
were analyzed to assess any differences that might predict more self-awareness. Although 
not significant, a trend existed indicating that females were more likely to have noticed 
their lesion (p = 0.78). As mentioned previously, familial patients were not more likely to 
have discovered their own melanoma. Patients who had detected their own melanoma 
were more likely to have tumors located on the head and neck, anterior trunk, or 
extremities as opposed to tumors of the posterior trunk (p = 0.001). Patients noticing 
their own melanoma were no more likely to have had non-melanoma skin cancers prior to 
or subsequent to the diagnosis of their melanoma (p = 0.39), have had biopsies within the 
five years prior to melanoma (p = 0.23), differ in age (p = 0.94), or think they had more 
nevi, irregular nevi or larger nevi than average (p = 0.21; 0.55; 0.60, respectively). 
Interestingly, a majority of patients who had detected their melanoma thought they had 0- 
32 total body nevi (p = 0.02), as compared to estimates of greater numbers of nevi among 
other patients including the group whose melanoma was discovered by a physician (p = 
0.005). In addition, those patients who had noticed their own lesion were more likely to 
underestimate their total body nevi count, while the patients whose melanoma was 
discovered by someone besides themselves tended to overestimate their nevi count when 
compared to the physician’s estimate (p = 0.001; 0.001, respectively). 
Familial melanoma patients were more likely than sporadic patients to report a 
positive familial history of atypical nevi (p = 0.02). We were not able to document many 
of these reports either clinically or histologically. 
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Discussion 
Family History of Melanoma 
It has been estimated that approximately 10% of melanomas are familial in origin. 
In our study, 51 (23.6%) of the patients had a positive family history of melanoma when 
including first- and second-degree relatives, and 31 (14.5%) were familial melanoma 
patients when only including first-degree relatives. To date, only a few studies have 
compared sporadic and familial melanoma directly. One previous study consisted of 7 
(4.6%) familial melanoma patients of a total of 151 patients with melanoma; the family 
members’ melanomas were undocumented. (Barnhill, 1992) Six patients had at least one 
first-degree relative affected while the seventh reported two second-degree relatives. 
Another study completed in France compared 22 (8%) familial patients to 273 sporadic 
patients. (Grange, 1995) Fourteen patients had at least one histologically confirmed first- 
degree relative with the diagnosis of melanoma while the remaining eight had 
histologically confirmed second- or third-degree relatives with melanoma. Kopf et al. 
(1986) studied a cohort consisting of 69 (5.9%) familial patients and 1100 sporadic 
patients. No histologic or clinical documentation of first- or second-degree relatives is 
mentioned. 
Of the 31 patients with at least one first-degree relative with melanoma, 85.3% of 
the family members’ melanomas were histologically confirmed, and of the 20 patients with 
a second-degree relative with melanoma, 75% of the relatives’ melanomas were 
confirmed. The importance of confirmation of patients’ reports concerning family 
members lies in the fact that non-melanoma skin cancers can be confused with melanoma. 

34 
For example, Aitken et al. (1994) found that 44.5% of positive family histories were false 
positives. In this study, we did not observe such a high false positive rate. Medical 
records of only two family members failed to confirm melanoma (one family member had 
an atypical nevus while a second had a basal cell carcinoma). Even if those first- and 
second-degree relatives who lacked confirmation are excluded from our study, 41 patients 
(19.2%) would still be considered familial. However, as the Yale Pigmented Lesion Clinic 
serves as a regional tertiary care site, the number of difficult cases, e g., patients with 
multiple primaries, positive family histories, and numerous atypical moles, would 
presumably be represented disproportionately. However, having at least the estimated 
proportion of familial patients in a study increases the likelihood of observing any true 
differences. 
Most studies, including ours, found no phenotypic differences between sporadic 
and familial patients. (Barnhill, 1992) Grange et al. (1995), however, found a significant 
association with red hair and an inability to tan in familial patients. In addition, the 
majority of studies have a greater proportion of females (Barnhill, 1992; Grange, 1995), 
and in our study as well, the proportion of females was greater in both the familial and 
sporadic groups (all patients: F 61.2%; M 38.8%). Of note, approximately the same 
proportion of males and females reported a positive family history, which indicates the 
absence of bias in the sexes’ knowledge of family medical history. 
Surprisingly, among Barnhill’s (1992) patient cohort, familial patients were on 
average older at the time of diagnosis (52.3 years vs. 46.7 years). Although our results 
were not significant, we have found, as have others (Grange, 1995), that familial patients 
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tend to be younger at diagnosis (this study: 41.8 years vs. 45.4 years) (Table 4). It is 
thought that familial patients are younger at the time of diagnosis because of earlier 
detection based upon increased medical surveillance and because of development of 
melanoma at an earlier age. 
While melanoma clusters in some families because of a mutated gene causing 
melanoma susceptibility or increased numbers of dysplastic nevi which predispose to 
melanoma, all familial patients do not segregate into these categories. Melanoma may 
cluster in some families because of increased UV light exposure or increased susceptibility 
to UV light. Neither Barnhill et al. (1992) nor Kopf et al. (1986) reported a difference in 
the number of total body nevi or clinically atypical nevi, but Grange et al.’s (1995) and 
Aitken et al.’s (1994) familial patients tended to have a higher total body nevus count. In 
our patients, a trend of more clinically atypical nevi existed (> 6 AN: F 45.1%; S 29.7%, p 
= 0.02). At this time, it is difficult to clearly define differences in the skin of familial and 
sporadic melanoma patients. 
In our study, the Breslow depths of the melanomas did not differ between the two 
groups, suggesting that lesions in familial patients were not removed earlier in the disease. 
While Grange et al.’s (1995) and Kopf et al.’s (1986) results agreed with ours, Barnhill et 
al. (1992) have reported thinner lesions in familial patients (i.e., F 1.54 mm, S 2.11 mm). 
Greene (1985b) reported a thinner Breslow depth among familial patients compared to 
that of an unselected population, but the results may be biased, as only familial patients 
were being studied directly. All concur that the histologic grouping of melanomas does 
not differ among the two populations. 
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The results of our multivariate analysis of familial patients versus sporadic 
patients differed somewhat from those of prior studies. Aitken et al. (1994) report an 
association of familial patients with poorer tanning ability, lighter skin color and a greater 
number of total body nevi while Grange et al. (1995) found a higher incidence of red hair 
and clinically atypical nevi. We found an association with a familial history of atypical nevi 
and non-melanoma skin cancer (Table 6). Familial melanoma patients may be able to 
describe family members’ nevi more accurately than sporadic patients. A family history of 
non-melanoma skin cancer may be a reflection of tanning ability, skin color or cumulative 
sun exposure. An association between the development of a second primary melanoma 
and a family history of melanoma was found in multivariate but not univariate analysis. 
This finding has been reported previously in a prospective study of familial patients. 
(Greene, 1985) One group’s analysis is not more true than another, because results will 
vary depending on the variables entered and the different means by which they were 
measured. 
Prior Dermatologic Surveillance 
Given that early detection of melanoma can improve survival, skin cancer 
screening has received much attention. (Tucker, 1988; Geller, 1992a & 1992b; Roush, 
1992) Visual screening by qualified health care providers should increase the proportion 
of melanomas diagnosed at an early stage. (Koh, 1991) Geller et al. (1992a) studied the 
use of health services prior to the diagnosis of cutaneous melanoma in a group of patients 
diagnosed with melanoma between January 1 and December 31, 1987. The study did not 
include a control population. Through questioning of approximately half of the patients. 

37 
the group found that, compared to published figures of national population utilization, a 
slightly higher proportion of these patients had regular physicians and had seen the 
physician more often in the past year (87% versus 82% and 67% versus 63%, 
respectively). Only 20% of the patients had their skin examined in the year prior to 
diagnosis, while only 24% had examined their own skin. Eleven percent of this patient 
population was labeled as having a family history of melanoma, although it is not 
mentioned how this group was designated nor whether the history was substantiated. Of 
the familial melanoma patients, only 24% responded that they saw a dermatologist on a 
regular basis, compared to 20% of all of the study patients. 
By examining the number of skin biopsies in the years prior to the diagnosis of 
melanoma as a measure of surveillance by medical personnel, we also studied whether 
familial melanoma patients were being screened. We found that while patients with a 
positive family history of melanoma did have more benign skin biopsies performed at any 
time prior to their melanoma diagnosis (p = 0.02), patients with a family history of 
melanoma did not have more skin biopsies performed in the one year, two years or five 
years prior to the diagnosis of melanoma than did sporadic melanoma patients (Table 8). 
In addition, having had a skin biopsy performed prior to the diagnosis of melanoma and 
therefore having been under medical surveillance did not predict a melanoma of thinner 
depth among either familial or sporadic melanoma patients (Table 7). Since melanoma, 
with the exception of nodular melanoma, would be apparent on the skin as a suspicious 
lesion for at least a year prior to its diagnosis, one possible explanation is that these 
patients did not undergo full-body skin examination. The results also suggest that among 
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medical personnel, dermatologists do diagnose lesions at an earlier stage than do other 
physicians. 
Why are familial melanoma patients not receiving greater skin surveillance? Part 
of the onus lies with medical personnel who must stress the importance of screening for 
skin cancer. A 1989 survey of New England dermatologists found that 70% regularly 
recommended family screening to melanoma patients. (Geller, 1992b) In the Pigmented 
Lesion Clinic, patients are regularly reminded to have at least first-degree relatives 
undergo a full-body skin exam. In reviewing medical records, however, it appears that not 
all patients take this suggestion seriously. The charts reveal that when patients are asked 
about the results of family screening, they respond that members have not yet been 
screened. Attempts to offer free public screening to relatives of patients with melanoma 
have met with somewhat limited success, (unpublished observation) Possibly the relatives 
fear the results of a screening exam or may not consider themselves at risk. 
Post-Melanoma Dermatologic Surveillance 
Dermatologic surveillance after the diagnosis of cutaneous melanoma is important 
not only for early detection of recurrence or progression of disease, but also for screening 
for the development of another primary melanoma. It is estimated that approximately 6% 
of patients develop multiple primary melanomas. Our data, as did that of others (Carey, 
1994), demonstrate that subsequent melanomas are thinner (1st: 1.1 + 1.2 mm; 2nd: 0.5 + 
0.8 mm). 
Following diagnosis of melanoma, multiple biopsies are performed. The majority 
are of nevi and benign growths. When familial and sporadic patients were compared, the 
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familial group was found to have more atypical nevi removed in the first five years after 
melanoma (p = 0.007). This does not suggest that sporadic patients should not have 
suspicious nevi removed as 0.005 secondary melanomas were diagnosed based on each 
nevi biopsied. 
Patient Perception 
Our data demonstrates that melanoma patients can accurately estimate their 
number of moles (p = 0.001) and determine an increased number of nevi (p = 0.001) or 
larger nevi (p = 0.02) compared to the general population. This suggests that these 
patients are aware that something is different about their skin. Our results do indicate that 
patients were more likely to detect their melanoma if it was not located on their posterior 
trunk. However, patients who were the first to notice their suspicious pigmented lesion 
and bring it to medical attention did not have thinner lesions. In fact, their melanomas 
were deeper (Table 7). This emphasizes the need for patient education. 
Conclusion 
In summary, this study has directly compared familial (n = 51) and sporadic (n = 
163) patients seen in the Yale Pigmented Lesion Clinic between January 31, 1995 and 
January 31, 1996. Familial melanoma patients were found to develop melanoma at a 
younger age (p = 0.05) and to have had more benign biopsies performed prior to their 
diagnosis of melanoma (p = 0.02). The two patient populations did not differ in their sex 
distribution, hair and eye color, or the ability to tan/bum. In addition, no difference 
between the two populations was seen when comparing the histology, Breslow depth, or 
site of their respective melanomas. Multivariable analysis showed that predictors of a 
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positive family history of melanoma included a personal history of melanoma, a family 
history of non-melanoma skin cancer, and a surrogate report of familial atypical nevi. 
Excluding the greater number of benign skin biopsies performed on familial melanoma 
patients prior to their diagnosis of melanoma, the number of skin biopsies performed 
within the five years prior or at any time prior to the diagnosis was the same between the 
familial and sporadic melanoma patients. 
Patients who had skin biopsies performed in the years prior to a melanoma 
diagnosis did not have thinner melanomas. One explanation is that patients might not be 
receiving full-body skin examinations in the year prior to their melanoma diagnosis. The 
ability of dermatologists to detect early melanomas was demonstrated. Dermatologists 
were much more likely than other physicians or the patients themselves to diagnose lesions 
at an earlier point in development. Screening by dermatologists would greatly reduce the 
number of patients who do develop advanced melanoma. The benefit of skin examinations 
is also evident after seeing that second primary lesions are diagnosed at a thinner Breslow 
depth. 
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Table 1: Summary of Familial Melanoma Case Reports 
Authors Year of 
Publication 
Proband and Relative(s) 
Cawley 1951 male, son and daughter 
Greifelt 1952 male and father 
Moschella 1961 female and sister 
Miller et al. 1962 male and daughter 
female and mother 
female and mother 
male and maternal grandfather 
male and mother 
female and maternal grandfather 
female and sister 
female and sister 
Schoch 1963 male, mother and brother 
Salamon et al. 1963 female and father 
male and mother 
female and maternal grandfather 
female and paternal aunt 
Turkington 1965 female and maternal aunt 
male and mother 
male and maternal grandfather 
female and father 
female and father 
male and maternal and paternal 
grandfathers 
female, sister and father 
male, sister and maternal and 
paternal uncles 
female and sister 
female and maternal cousin 
female and father 
male and paternal grandfather 
female and mother 
male, father and paternal cousin 
male and father 
Katzenellenbogen et al. 1966 fraternal twins(male and female) 
Smith et al. 1966 female and son 
Anderson et al. 1967 female, mother, maternal aunt 
and uncle, maternal cousin, 10 
distant maternal relatives 
(question if 7 were documented) 
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Table 1: Summary of Familial Melanoma Case Reports 
Authors Year of 
Publication 
Proband and Relative(s) 
Andrews 1968 male and sister 
St-Ameault et al. 1969 male identical twins 
Lynch et al. 1978 male, sister, mother, maternal 
aunt, maternal grandfather and 
his sister, and maternal 
grandmother and her sister 
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Table 2: Histologic Criteria for Atypical or B-K Moles 
FAMMM Syndrome B-K Mole Syndrome 
Compound nevus Compound nevus 
Melanocytic dysplasia (mild to severe) Atypical melanocytic hyperplasia 
Fibroplasia of the papillary dermis (variable) Fibroplasia of the papillary dermis 
Lymphocytic infiltrate of the papillary 
dermis (variable—may or may not be 
present) 
Lymphocytic infiltrate of the papillary 
dermis 
Histology not always similar to a regressing 
malignant melanoma or halo nevus 
Histology similar to a regressing malignant 
melanoma or halo nevus 
Table 3: Marker Location From 9pter to 
Proximal 9p 
D9S156-D9S157-D9S162-IFNA-D9S736-D9S171- 
D9S126-D9S169-D9S104 
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TABLE 4: ClinicaH Characteristics of Patients 
+ Family History 
(n=51) 
n (%) 
- Family History 
(n=163) 
n (%) 
P value 
Sex 0.62 
Female 33 (64.7%) 98 (60.1%) 
Male 18 (35.3) 65 (39.9) 
Age at 1st 
Melanoma 
0.05 
0 < years < 25 2 (3.9) 11 (6.8) 
25 < years < 45 33 (64.7) 73 (44.8) 
45 < years < 65 15 (29.4) 60 (36.8) 
years >65 1 (2.0) 19(11.6) 
Eye Color 0.46 
Blue 22 (43.1) 66 (40.0) 
Green 3 (5.9) 22 (13,3) 
Hazel 6(11.8) 32 (19.4) 
Grey 1 (2.0) 4 (2.4) 
Light Brown 7 (13.7) 13 (7.9) 
Dark Brown 11 (21.6) 26(15.8) 
Hair Color 0.72 
Blond 9(17.7) 30(18.2) 
Red 2 (3.9) 12 (7.3) 
Light Brown 12(23.5) 52 (31.5) 
Dark Brown 26 (51.0) 66 (40.0) 
Black 1 (2.0) 4 (2.4) 
Skin Burnability 0.39 
Severe Sunburn 
(Blistering) 
4(7.8) 11(6.7) 
Painful Sunburn 
(Peeling) 
23 (45.1) 78 (47.3) 
Mildly Burned 
(with Tanning) 
22 (43.1) 60 (36.4) 
Brown 
(no Sunburn) 
2 (3.9) 6(3.6) 
Skin Tannability 0.69 
Deeply Tanned 7 (13.7) 22 (13.3) 
Moderately 
Tanned 
31 (60.8) 93 (56.4) 
Mildly Tanned 
(Hx Peeling) 
9(17.7) 34 (20.6) 
No Suntan 
(Freckling) 
2 (3.9) 12 (7.3) 
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Table 5: Family Members with Melanoma - Not Histologically < Confirmed 
Age at Diagnosis 
(yrs) 
Site Outcome 
Patient 1 (Sister) 29 posterior trunk alive and well 
Patient 2 (Sister) unknown unknown alive and well 
Patient 3 (Sister) 45 arm alive and well 
Patient 4 (Sister) 24 right arm alive and well 
Patient 5 (Father) 57 head and neck deceased 
Table 6: Multivariable Analysis - Predicting a Positive Familial Melanoma History 
Odds Ratio 95% Confidence Interval 
+ Family History of Non- 
Melanoma Skin Cancer 
2.08 1.07-4.05 
Surrogate Report of 
Atypical Nevi in Family 
Members 
2.27 1.16-4.43 
Second Primary Melanoma 2.40 1.12-5.15 
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Table 7: 
Melanoma Characteristics 
+ FH 
(n=51) 
n (%) 
- FH 
(n=163) 
n (%) 
P 
value 
Female 
(n=131) 
n (%) 
Male 
(n=83) 
n (%) 
P 
value 
Mean 
Breslow 
Depth 
(in mm) 
Histology 0.73 0.17 
Superficial Spreading 37 
(72.6) 
120 
(76.0) 
97 
(75.2) 
60 
(75.0) 
0.86 
Nodular 6 
(11.8) 
19 
(12.0) 
11 
(8.5) 
14 
(17.5) 
2.40 
Lentigo Maligna 1 
(20) 
0 
(0) 
1 
(0.8) 
0 
(0) 
0.30 
Acrolentiginous 1 
(2.0) 
1 
(0.6) 
2 
(1.5) 
0 
(0) 
0.45 
Desmoplastic 1 
(2.0) 
2 
(1.3) 
3 
(2.3) 
0 
(0) 
5.5 
Unclassified 5 
(9.8) 
16 
(10.1) 
15 
(11.6) 
6 
(7.5) 
0.84 
Site 0.30 0.001 
Head & Neck 7 
(13.7) 
16 
(9.8) 
11 
(8.4) 
12 
(14.5) 
Posterior Trunk 8 
(15.7) 
52 
(31.9) 
26 
(19.9) 
34 
(41.0) 
Anterior Trunk 10 
(19.6) 
21 
(12.9) 
11 
(84) 
20 
(24.1) 
Upper Extremity 8 
(15.7) 
34 
(20.9) 
36 
(27.5) 
6 
(7.2) 
Lower Extremity 18 
(35.3) 
39 
(23.9) 
46 
(35.1) 
11 
(13.3) 
Other 0 
(0) 
1 
(0.6) 
1 
(0.8) 
0 
(0) 
Breslow Depth (in mm) 0.56 0.24 
BD < 0.75 29 
(59.2) 
80 
(52.6) 
73 
(59.3) 
36 
(46.2) 
0.75 <BD< 1.5 11 
(22.5) 
41 
(27.0) 
29 
(23.6) 
23 
(29.5) 
1.5 < BD < 4.0 8 
(16.3) 
29 
(19.1) 
20 
(16.3) 
17 
(21.8) 
BD > 4.0 1 
(2.0) 
2 
(1.3) 
1 
(0.8) 
2 
(2.6) 
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Table 8: Biopsies Prior to the 
Diagnosis of Melanoma 
+ FH - FH P value 
(n=51) (n=163) 
n (%) n (%) 
Total # in 5 Years Prior 
Atypical Nevi 0 47 (92.2) 151 (92.6) 1.00 
>1 4(7.8) 12 (7.4) 
Benign Nevi 0 42 (82.4) 149 (91.4) 0.07 
>1 9 (17.7) 14 (8.6) 
Non-Nevi Benign 0 45 (88.2) 143 (87.7) 0.92 
>1 6 (11.8) 20(12.3) 
Non-Melanoma 0 50 (98.0) 152 (93.2) 0.30 
Skin Cancer >1 1 (2.0) 11 (6.8) 
All Lesions 0 36 (70.6) 128 (78.5) 0.25 
>1 15 (29.4) 35 (21.5) 
Total # At Any Time Prior 
Atypical Nevi 0 47 (92.2) 150 (92.2) 1.00 
>1 4(7.8) 13 (8.0) 
Benign Nevi 0 36 (70.6) 138 (84.7) 0.03 
>1 15 (29.4) 25 (15.3) 
Non-Nevi Benign 0 43 (84.3) 134(82.2) 0.73 
>1 8 (15.7) 29(17.8) 
Non-Melanoma 0 50 (98.0) 151 (92.6) 0.31 
Skin Cancer >1 1 (2.0) 12(7.4) 
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Table 9: Predictors of Breslow 
Depth (in mm) (All Patients) 
n = 201 BD < 
0.4 mm 
n (%) 
0.4 mm < 
BD < 0.75 
mm 
n (%) 
0.75 mm < 
BD< 1.5 
mm 
" (%) 
BD > 
1.5 mm 
n (%) 
P 
value 
Biopsy Hx 
Skin Bx in 1 yr Prior 0 43 
(25.2)) 
47 
(27.5) 
48 
(28.1) 
33 
(19.3) 
0.40 
> 1 11 
(36.7) 
8 
(14.6) 
4 
(13.3) 
7 
(23.3) 
Skin Bx in 2 yrs Prior 0 43 
(25.6) 
46 
(27.4) 
46 
(27.4) 
33 
(19.6) 
0.50 
> 1 11 
(33.3) 
9 
(27.3) 
6 
(18.2) 
7 
(21.2) 
Skin Bx in 5 yrs Prior 0 38 
(24.7) 
44 
(28.6) 
42 
(27.3) 
30 
(19.5) 
0.51 
_> 1 16 
(34.0) 
11 
(23.4) 
10 
(21.3) 
10 
(21.3) 
Prior Non-Melanoma Skin Cancer 0.09 
Yes 13 
(22.9) 
13 
(22.9) 
15 
(26.3) 
16 
(28.1) 
No 41 
(28.5) 
42 
(29.2) 
37 
(25.7) 
24 
(16.7) 
Noticed Melanoma 
Self 18 
(18.6) 
25 
(25.8) 
31 
(32.0) 
23 
(23.7) 
0.005 
Physician, Friend, Family 36 
(34.6) 
30 
(28.9) 
21 
(20.2) 
17 
(16.4) 
Self 18 
(18.6) 
25 
(25.8) 
31 
(32.0) 
23 
(23.7) 
0.001 
Physician 22 
(45.8) 
14 
(29.2) 
8 
(16.7) 
4 
(83) 
Physician: Non-Dermatologist 8 
(38.1) 
4 
(19.1) 
5 
(23.8) 
4 
(19.1) 
0.05 
Dermatologist 14 
(51.9) 
10 
(37.0) 
3 
(HD 
0 
(0) 
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1 Two copies of each tumor suppressor gene exist in each cell. Familial predisposition to cancer in the 
tumor suppressor model originated from studies of retinoblastoma and the ‘two-hit’ formulation. One 
defective allele (whose protein product is defective in suppressing tumor growth) is inherited. The protein 
product of the second allele suppresses tumorigenesis, but mutation or deletion of this allele unleashes the 
suppressor effect. 
2MTS1 is also known as CDK41, plb1141"4 5 6 gene and CDKN2. 
3 In addition. Walker et al. (1995) reported a 55-100% penetrance of the different mutations in the 
kindreds. 
4 Within one kindred, the authors reported that two family members were homozygous for the deletion, 
demonstrating that homozygotes are viable despite the loss of a cell cycle regulator. One member had not 
had a melanoma at the time of the first evaluation at age 54 but died a year later of an adenocarcinoma. 
Two of her three children did have melanoma. The authors point out that although it would be rare to 
find two homozygotes in the given number of patients, they were from an endogamous region. 
5 Luca et al. (1995) reported similar results. 
6 A recent study, which proved that mutations within p53 do not play a large role in melanoma 
tumorigenesis, did find C:G to T:A transitions in p53 in 20% of the metastatic melanomas consistent with 
UV radiation damage. (Hartmann, 1996) 
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